Green light from the European Medicines Agency (EMA). The regulator announced this Thursday, November 11, that it had approved for the first time the marketing in the European Union of two monoclonal antibody treatments against the coronavirus.
→ THE FACTS. Covid-19: monoclonal antibodies authorized for the immunocompromised
The European Medicines Agency (EMA) said it has approved the use of a treatment from the Swiss pharmaceutical company Roche, Ronapreve, and a treatment from the South Korean company Celltrion, regdanvimab. “Ronapreve and Regkirona are the first drugs based on monoclonal antibodies to receive a positive opinion (…) against Covid-19”, said the Amsterdam-based EMA.
An “important step”
EU Health Commissioner Stella Kyriakides said approval of the two drugs was a “Milestone” against the disease, the EU relying so far on four vaccines.
→ EXPLANATION. Molnupiravir, paxlovid: what can new treatments for Covid-19 change?
“With increases in Covid-19 contamination in almost all Member States, it is reassuring to see many promising treatments in development as part of our therapeutic strategy against Covid-19”, she said. “Today we are taking an important step towards our goal of authorizing up to five new treatments in the EU by the end of the year”, she added.
Antibodies are one of the building blocks of our immune system. Faced with the presence of a dangerous element, such as a virus, our body naturally produces it to identify the invader. The idea of synthetic antibodies is to select natural antibodies and reproduce them artificially to then administer them in treatment, generally by infusion.